Blog

The moment that Hannah Earle was diagnosed with breast cancer, she was holding a fussy baby on her hip while her older daughter was also upstairs crying. Her husband walked in the door from an errand and he saw it on her face. Her entire world was spinning — she had no family history, she was young, healthy, in the midst of breastfeeding her second child, and her family had just booked their first international trip together.

Read as Renee Man, a brain cancer patient and mom to three beautiful children, discusses her journey from diagnosis to clinical trial participant.

What is the difference between DtP and Virtual Trials, and why is it such an important distinction? Below are key considerations as trial professionals develop different scenarios over the next 18 months.

If you are looking for innovation and better results for your trial, the selection process itself should ensure that the vendor shares the same vision. How do you do that? By asking the right questions. Here are 5 to get you started.

It's been 6 months since COVID-19 was declared a pandemic. Without a vaccine, there is a probability of a second wave. How can we apply what we've learned so far to help us prepare for the future?

With complex oncology studies, mid-study changes are the norm, but disruptions from downstream impacts don’t have to be. Here are 5 supply chain impacts resulting from master protocol amendments– and how to best prepare.

With master protocols, each site has to perform its own approval process in order to begin working under a new protocol version, resulting in multiple protocol versions being used at the same time. How can you manage this? Here are 3 simple steps.

A master protocol acts like a map showing many paths a clinical trial may take, where the sponsors don’t know in which direction their study will evolve, until the trial is under way.

Q&A with a clinical research site discussing COVID-19 and the movement towards Direct-to-Patient trials.